RedHill Biopharma Ltd (RDHL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The companys commercial product portfolio consists of Donnatal for IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Release Capsules 49.3 mg for GERD and other GI conditions; and EnteraGam, a medical food intended for the dietary management. It sells these three specialty GI products in select US territories. RedHill is investigating pipeline candidates for the treatment of GI disorders and cancer that include helicobacter pylori infection, Crohns disease, multiple sclerosis and pancreatic cancer among others. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd (RDHL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 6
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14
Partnerships 15
RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15
RedHill Biopharma Enters into Agreement with ParaPRO 16
RedHill Biopharma Enters into Research Agreement with Aarhus University 17
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19
RedHill Biopharma Enters into Agreement with NIAID 20
RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21
Licensing Agreements 22
RedHill BioPharma Enters into Licensing Agreement with Entera Health 22
IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24
RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27
RedHill Biopharma Enters into Licensing Agreement with Temple University 28
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29
RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30
Equity Offering 31
RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 31
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 33
RedHill Biopharma Withdraws Public Offering of ADSs 35
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 36
RedHill Biopharma Completes Exercise of Underwriters Over Allotment Option for Public Offering of ADSs for USD14.4 Million 38
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 40
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 41
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 43
RedHill Biopharma Completes Private Placement Of Shares For US$7 Million 45
RedHill Biopharma Ltd - Key Competitors 47
RedHill Biopharma Ltd - Key Employees 48
RedHill Biopharma Ltd - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
May 08, 2018: RedHill Biopharma Reports First Quarter 2018 Financial Results 50
Feb 22, 2018: RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update 52
Nov 13, 2017: RedHill Biopharma Reports 2017 Third Quarter Financial Results 54
Jul 25, 2017: RedHill Biopharma Reports 2017 Second Quarter Financial Results 57
May 03, 2017: RedHill Biopharma Reports 2017 First Quarter Financial Results 59
Feb 23, 2017: RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results 60
Corporate Communications 62
Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 62
Product News 63
04/19/2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D 63
01/11/2017: RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections 64
Clinical Trials 66
May 30, 2018: RedHill Biopharma to Present Positive Phase II Results of BEKINDA for IBS-D at Digestive Disease Week 2018 66
May 14, 2018: RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohns Disease on May 15 67
May 07, 2018: RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohns Disease 68
Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting 69
Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D 70
Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D 71
Nov 09, 2017: RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohns Disease 72
Oct 23, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104 74
Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 75
Oct 02, 2017: RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohns Disease with Top-Line Results Expected Mid-2018 77
Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 79
Jul 31, 2017: RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohns Disease 80
Jul 17, 2017: RedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D 82
Jul 12, 2017: RedHill Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohns Disease 83
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 85
Jun 15, 2017: RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection 86
Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 88
May 04, 2017: RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 90
Apr 24, 2017: RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D 91
Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA 92
Mar 22, 2017: RedHill Biopharma to Present at the 2017 MAP Conference 93
Mar 21, 2017: RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohns Disease 94
Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 95
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 97
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda 99
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-104 100
Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-105 101
Jan 10, 2017: RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection 102
Jan 09, 2017: RedHill Biopharmas RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium 104
Jan 04, 2017: RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium 105
Other Significant Developments 106
Apr 09, 2018: RedHill Biopharma Provides Semi-Annual Business Update 106
Dec 05, 2017: RedHill Biopharma Provides 2017 Year-End Business Update 107
Aug 10, 2017: RedHill Biopharma Provides 2017 Semi-Annual Business Update 108
Mar 29, 2017: RedHill Biopharma: Notice of Annual General Meeting of Shareholders 111
Appendix 113
Methodology 113
About GlobalData 113
Contact Us 113
Disclaimer 113

List Of Tables

List of Tables
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 14
RedHill Biopharma Enters into Co-Marketing Agreement with Napo Pharma 15
RedHill Biopharma Enters into Agreement with ParaPRO 16
RedHill Biopharma Enters into Research Agreement with Aarhus University 17
Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 18
RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 19
RedHill Biopharma Enters into Agreement with NIAID 20
RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 21
RedHill BioPharma Enters into Licensing Agreement with Entera Health 22
IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 23
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 24
RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 25
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 27
RedHill Biopharma Enters into Licensing Agreement with Temple University 28
Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 29
RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 30
RedHill Biopharma Raises USD22.5 Million in Public Offering of American Depositary Shares 31
RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 33
RedHill Biopharma Withdraws Public Offering of ADSs 35
RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 36
RedHill Biopharma Completes Exercise of Underwriters Over Allotment Option for Public Offering of ADSs for USD14.4 Million 38
RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 40
RedHill Biopharma Completes Private Placement Of Shares And Warrants For US$11.7 Million 41
RedHill Biopharma Completes Private Placement Of Units For US$8.5 Million 43
RedHill Biopharma Completes Private Placement Of Shares For US$7 Million 45
RedHill Biopharma Ltd, Key Competitors 47
RedHill Biopharma Ltd, Key Employees 48
RedHill Biopharma Ltd, Subsidiaries 49

List Of Figures

List of Figures
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
RedHill Biopharma Ltd, Medical Devices Deals, 2012 to YTD 2018 11

RedHill Biopharma Ltd (RDHL) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The companys commercial product portfolio consists of Donnatal for

USD 250 View Report

Redhill Biopharma Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Redhill Biopharma Ltd Company Profile is a detailed strategic and analytical report on Redhill Biopharma Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Benitec Biopharma Ltd (BLT) - Medical Equipment - Deals and Alliances Profile

Benitec Biopharma Ltd (Benitec) is a research based clinical stage biotechnology company. The company develops novel therapeutics for the treatment of chronic and life threatening diseases based on its proprietary

USD 250 View Report

Redhill Biopharma Ltd Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Redhill Biopharma Ltd Company Profile is a detailed strategic and analytical report on Redhill Biopharma Ltd. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available